We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top-tier investors such as Pureos Bioventures, NEA, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Morningside Venture Investments, Jeito Capital, Versant Ventures, Novo Holdings and others.
Financed: $80M raised
New target/core pathway for fibrosis. Treatment of late-stage fibrosis, related cancers. Initially liver.
Financed: $157.5M raised
Antibody platform re-focusing IL-2 to CTLs to fuel anti-cancer immunity.
Incubating
First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach.
Incubating
Exploiting novel structures of mTOR complexes to develop new classes of inhibitors for mTOR-related disorders
Financed: $50M raised
Shielded cell therapies building on discovery of variants alleles allowing cells to preserve function while resisting immunotherapy depletion.
Stopped
Developing novel inflammasome inhibitors.
Financed: $16.7M raised
Highly potent and specific therapies based on T cell receptor (TCR), targeting of solid tumors.
Incubating
Platform to create compartment locked biologics for higher local retention and fast systemic degradation
Incubating
A novel class of immunosuppressive therapies for autoimmune inflammatory diseases and organ transplantation
Incubating
Antibody-based discovery platform against novel druggable secreted growth factors reprogramming diseased cells towards uncontrolled growth.
Financed
Gene logic circuits. In-vivo multifactorial identification and killing of cancer cells.
Incubating
Bacterial mixes as microbiome therapeutics in IBD and oncology based on mixed-culture technology.
Financed: $41.5M raised
Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies.
Incubating
Antibodies against novel stromal cell targets acting locally on the immune system to treat chronic immune-mediated diseases.
Financed: $25M raised
Novel targets that mediate endocannabinoid efficacy. Treatments for stress, anxiety etc.
Financed: $42M raised
Intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting.
Financed: $16.5M raised
Cancer drug resistance platform to develop small molecules addressing non mutational mechanisms of therapy evasion.
Sold
Functional ID of (neo)antigens for cancer, immunological and infectious diseases.
Financed: $18.5M raised
mRNA platform for local regenerative medicine-based therapeutics.
Incubating
Next generation biologics to rebalance the immune response in acute and chronic inflammation
